1st International Working Group on Thalassemia:

IS IT TIME TO REVISIT CLASSIFICATION OF THALASSEMIA SYNDROMES ?

September 15-16, 2017

Abstract Submission for Poster Sessions        Faculty Abstract Submission

Application Form – September, 15-16

Theoretical and Practical Training in

HAEMATOLOGICAL RARE DISEASES: from genetic counselling – through bench – to bed

September 15-23, 2017

Application Form – September, 15-23

CAMPUS OF HEMATOLOGY “Franco e Piera Cutino” A.O.R. “Villa Sofia – V. Cervello” Palermo (Italy)

Dear Colleague,

it is our pleasure to invite you to join us for the theoretical and practical training in HAEMATOLOGICAL RARE DISEASES: from genetic counselling – through bench – to bed which will take place in Palermo at the CAMPUS OF HAEMATOLOGY “Franco e Piera Cutino” A.O.R. “Villa Sofia – V. Cervello” from 15th to 23rd September, 2017.

The main purpose of the Course is to gather experienced scientists in the field of Haematological Rare Diseases at the same table with young Physicians (Haematologists, Gynecologists) and Biologists, Radiologists, Medical Technicians already committed to become experts in this field. The discussion will be on relevant topics related to Prenatal Diagnosis, Thalassemia Syndromes and Haemoglobinopathies, from basic research to clinical and therapeutic dilemmas.

The course will take place at the Campus of Haematology “Franco e Piera Cutino”, a pioneering center for prevention, care and research on Thalassemia and Haemoglobinopathies, and for the reception of patients’ families and their guests.

The structure was inaugurated on May 8, 2013 at the Hospital “V. Cervello”, A.O.O.R. “Villa Sofia – V. Cervello” of Palermo, under the agreement between the Foundation “Franco e Piera Cutino”, the Association for Research “Piera Cutino” Onlus, the U.O.C. Haematology for Rare Diseases of Blood and Haematopoietic Organs and the Health Department of the Regione Sicilia.

The Campus was entirely built thanks to private fundraising by the Association for Research “Piera Cutino”, a non-profit organization established in 1998 by the Cutino family.

The Campus of Haematology “Franco e Piera Cutino” stands out as center of excellence across the country, not only for clinical routine tasks but also for the several and exclusive current activities in different clinical and research settings with impact at national and international level.

This is possible thanks to the presence of highly skilled professionals involved in innovative research projects in collaboration with the Foundation “Cutino”.

Among the numerous activities carried out at The Campus we are proud to mention

  • Coelocentesis: exclusive technique of prenatal diagnosis on fetal cells from Coelomic fluid (the only Center in the world).
  • Prenatal diagnosis by Chorionic Villus Sampling and by Amniocentesis.
  • Tests to detect Thalassemia healthy carrier.
  • First level screening for ß -Thalassemia and Haemoglobinopathies.
  • Genetic studies for the identification of the CysticFibrosis healthy carrier.
  • Biobanking for Research “Anna Maria Ferrara Cutino”
  • Outreach and training activities
  • Erythroid Cell Culture for the study of HbF drug activation.

The course includes 15 attendees, Physicians and Researchers selected from different countries highly motivated in becoming experts in the field of Haematological Rare Diseases. Participants will be directly involved in performing the specific practical part of the course in the laboratory or in the clinic unit.

An international stuff of experts will facilitate exchange of opinions and expertise among participants and between participants and tutors.

The duration of the course will be of nine days (15-23 September).

Applicants may wish to attend the entire program divided in three modules or otherwise select one module out of three.

We would like to thank you in advance for your willingness to share your expertise and experiences with us at this important educational activity.

Looking forward to welcoming you to Palermo

Yours sincerely

Prof. Aurelio Maggio – Dr. Santina Acuto

Directors

EVENT WILL START IN
  • 00

    days

  • 00

    hours

  • 00

    minutes

  • 00

    seconds

Add to My Calendar 2016-05-04 12:00:00 2016-05-04 18:00:00 Europe/London Gather Event Theme Gather is a responsive event theme with many awesome features including add to my calendar feature. Awesome. huh? tockholm, Sweden

FACULTY (Speakers, Chairmen & Tutors)

Biography

Professor, Department of Paediatrics, Kuwait University

Head, Pediatric Hematology Unit, Mubarak Hospital, Kuwait

Director, Hemoglobin Research Laboratory, Department of Pediatrics, Kuwait University

Adjunct Professor, Center for Sickle Cell Research, University of Abuja, Nigeria

  • Current institution: Kuwait University, Mubarak Hospital, Kuwait, University of Abuja

 

  • Number of scientific papers and the main topics discussed:

130, mainly on sickle cell disease and thalassemia. I have led a team that has produced seminal papers on the genotype/phenotype characterization of patients with hemoglobinopathies in the Arabian Peninsula. One of our recent publications was on thalassemia intermedia.

  • Other positions in Scientific Societies or Scientific Journal:

Member of editorial boards of several journals including Hemoglobin and Medical Principles and Practice

Chairman, Nigerian Sickle Cell Disease Network

Co-Chairman, West African Sickle Cell Disease Network

Member, Novartis Oncology Advisory Committees for Thalassemia and Sickle Cell Disease in the Arabian Gulf and Africa

Director of the Kuwait National Sickle Cell Disease Registry

Dr Yesim Aydinok

Department of Paediatric Haematology, Ege University Children’s Hospital, and Ege University Hospital Blood Bank, Izmir, Turkey

Biography

Yesim Aydinok graduated from Ege University Medical School in 1986. She was appointed as a

paediatrician in 1992, and then as a paediatric haematologist in 1999 at Ege University Medical

School. Professor Aydinok studied haemoglobinopathies in Royal Free Hospital School of Medicine in London, UK; and clinical haematology in Great Ormond Street Hospital in London, UK as visiting Lecturer and Senior Lecturer respectively. She was appointed Professor of Paediatric Haematology at the Ege University Children’s Hospital in 2005, having previously been Associate Professor. Professor Aydinok was appointed Director of the University Hospital Blood Bank in 1999.

Thalassaemia is the main focus of Professor Aydinok’s clinical studies and research. She has been involved in clinical trials for new iron chelators since 2003 as well as clinical studies for and blood safety. Professor Aydinok has published 98 peer-reviewed articles, mostly in the field of thalassaemia.

She is serving as Associate Editor in Hematology Journal. She is a member of the American Society of Hematology (ASH) and the European Hematology Association (EHA). Professor Aydinok has been the Director of Haemoglobinopathy Working Group of Turkish Society of Haematology and Director of Transfusion Medicine, Blood Banking and Haemapheresis subcommittee of Turkish Society of Haematology.

Dr Caterina Borgna Pignatti

Biography

Medical Degree magna cum laude at the University of Pavia

Educational Council for Foreign Medical Graduates (ECFMG) 1972

Medical Fellow in Pediatric Hematology at Stanford University, California from March 1972 to February 1974.

Stage in Pediatric Hematology and Hepatology, University of Paris-Sud, France from January to November 1975

Specialty Degree in Pediatrics and Hematology at the University of Pavia, Italy

From October 1978 is Assistant Professor at the Pediatric Dept of the University of Pavia, Italy

In November and December 1981 works at the Fred Hutchinson Cancer Research Center di Seattle (USA) where she performs the first bone marrow transplant for thalassemia in one of her Italian patients.

In 1982, as the winner of a fellowship of the Associazione Italiana per la Ricerca contro il Cancro spends three months al Fred Hutchinson Cancer Research Center di Seattle (USA)

From 1994 Associate Professor of Pediatrics at the University of Ferrara, Italy,

From 2001 is Full Professor and Chief of Pediatrics at the University of Ferrara

She has published more than 150 indexed papers mainly in Pediatric Hematology, with a particular interest for Thalassemia.

She coauthored the first paper on bone marrow transplantation for thalassemia

Recent work has involved survival in thalassemia, the role of chelation in protecting from cardiac complications, the risk of malignancy, the prevalence and course of hepatocellular carcinoma.

Dr Marie Charlotte Bouesseau

Advisor, Service Delivery and Safety (SDS) World Health Organization Geneva,Switzerland

Biography

  • Coordinating a number of global projects related to innovation in service delivery which includes a global initiative on genomics and global health; collaborative work on the strengthening of integrated palliative care; ethical aspects of quality of care and clinical intervention in particular in the areas of medical products of human origin and person centered care.

Maria Domenica Cappellini

UI Designer

Biography

Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Aenean eu leo quam. Pellentesque ornare sem lacinia quam venenatis vestibulum. Sed posuere consectetur est at lobortis. Cras mattis consectetur purus sit amet fermentum.

Curabitur blandit tempus porttitor. Nullam quis risus eget urna mollis ornare vel eu leo. Nullam id dolor id nibh ultricies vehicula ut id elit.

Etiam porta sem malesuada magna mollis euismod. Cras mattis consectetur purus sit amet fermentum. Aenean lacinia bibendum nulla sed consectetur.

Vivamus sagittis lacus vel augue laoreet rutrum faucibus dolor auctor. Duis mollis, est non commodo luctus, nisi erat porttitor ligula, eget lacinia odio sem nec elit. Morbi leo risus, porta ac consectetur ac, vestibulum at eros.

Sub-heading

Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.

Aenean lacinia bibendum nulla sed consectetur. Etiam porta sem malesuada magna mollis euismod. Fusce dapibus, tellus ac cursus commodo, tortor mauris condimentum nibh, ut fermentum massa.

Another heading

Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Aenean lacinia bibendum nulla sed consectetur. Etiam porta sem malesuada magna mollis euismod. Fusce dapibus, tellus ac cursus commodo, tortor mauris condimentum nibh, ut fermentum massa justo sit amet risus.

  • Praesent commodo cursus magna, vel scelerisque nisl consectetur et.
  • Donec id elit non mi porta gravida at eget metus.
  • Nulla vitae elit libero, a pharetra augue.

Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Aenean lacinia bibendum nulla sed consectetur. Etiam porta sem malesuada magna mollis euismod. Fusce dapibus, tellus ac cursus commodo, tortor mauris condimentum nibh, ut fermentum massa justo sit amet risus.

Penatibus et magnis dis parturient montes, nascetur ridiculus mus. Aenean lacinia bibendum nulla sed consectetur. Etiam porta sem malesuada magna mollis euismod. Fusce dapibus, tellus ac cursus commodo, tortor mauris condimentum nibh, ut fermentum massa justo sit amet risus.

All session by Carol Wood

Registrations

PLENARY ROOM (Aula Magna “M. Vignola”)

08.00 | 08.30

Welcome address

Antonis Kattamis (Greece), Aurelio Maggio (Italy), Ali Taher (Lebanon)

08.30 | 08.45

Greetings from local Authorities

08.45 | 09.00

Introduction: Is it time to revisit classification of Thalassemia Syndromes ?

Aurelio Maggio (Italy)

09.00 | 09.15

THALASSEMIA MAJOR AND ANTIVIRAL TREATMENT

CHAIRPERSONS: Antonis Kattamis (Greece), Antonio Piga (Italy)

SESSION I

Transfusion therapy: what is new with respect to safety and control of iron loading?

Yesim Aydinok (Turkey)

09.15 | 09.30

The future of thalassemia patients without HCV infection: a new history

Vito Di Marco (Italy)

09.30 | 09.45

Interactive Discussion: what is the state of art in transfusion safety and anti-viral treatment of Thalassemia Syndromes worldwide ? Comparing experiences from France, India, Iran, Italy, Saudi Arabia:

Caterina Borgna Pignatti (Italy), Mahmoud Hajipour (Iran), Olivier Hermine (France), Farrukh Shah (KSA), Alok Srivastava (India)

09.45 | 10.30

Discussion

10.30 | 10.45

Coffee Break

10.45 | 11.00

THALASSEMIA INTERMEDIA

CHAIRPERSONS: Caterina Borgna Pignatti (Italy), Vip Viprakasit (Thailand)

SESSION II

Thalassemia Intermedia: is disease morbidity as we know it today less severe than Thalassemia Major ?

Ali Taher (Lebanon)

11.00 | 11.20

Hypercoagulable state in thalassemia

Eliezer Rachmilewitz (Israel)

11.20 | 11.40

General insights and current management of Thalassemia Intermedia

Maria Domenica Cappellini (Italy)

11.40 |12:00

Interactive Discussion: what is the state of art in Thalassemia Intermedia management worldwide ? Comparing experiences from Iran, Italy, Malaysia, Qatar:

Ibrahim Hishamshah (Malaysia), Mehran Karimi (Iran), Paolo Ricchi (Italy), Mahamoud Yassin (Qatar)

12.00 | 12.40

Discussion

12.40 | 13.00

Light Lunch

13.00 | 14.00

THE NEW ERA OF CHELATION TREATMENT

CHAIRPERSONS: Adriana Ceci (Italy), Alan Cohen (USA)

SESSION III

How the era of the new chelators is changing prognosis of Thalassemia Syndromes

John Porter (UK)

14.00 | 14.15

Effectiveness and safety of 10 different regimens for controlling iron overloading in Thalassemia Major

Aurelio Maggio (Italy)

14.15 | 14.30

Iron overload and Chelation Therapy in Thalassemia Intermedia

Ali Taher (Lebanon)

14.30 | 14.45

Interactive Discussion: what is the state of art in chelation management of Thalassemia Syndromes worldwide ? Comparing experiences from Italy, Kuwait, Oman, Pakistan:

Kunle Adekile (Kuwait), Shahina Daar (Oman), Aldo Filosa (Italy), Saqib Hussein Ansari (Pakistan)

14.45 | 15.30

Discussion

15.30 | 15.45

HIGHLIGHTS IN MANAGEMENT OF THALASSEMIA SYNDROMES IN EASTERN COUNTRIES

CHAIRPERSONS: Marie-Charlotte Bouesseau (Switzerland), Suthat Fucharoen (Thailand)

SESSION IV

Management of Thalassemia Syndromes in Egypt: what has been changing during the last 10 years?

Amal El-Beshlawy (Egypt)

15.45 | 16.05

Current management of Thalassemia Syndromes in Thailand: past, present and future

Vip Viprakasit (Thailand)

16.05 | 16.25

Discussion

16.25 | 16.45

MRI AND CURRENT MANAGEMENT OF THALASSEMIA SYNDROMES

CHAIRPERSONS: Gian Luca Forni (Italy), Paul Telfer (UK)

SESSION V

The impact of MRI in changing prognosis of Thalassemia Major

Dudley Pennell (UK)

16.45 | 17.05

The MIOT network: an Italian model for management of Thalassemia Syndromes

Alessia Pepe (Italy)

17.05 | 17.25

Interactive Discussion: what is the state of art in MRI facilities worldwide? Comparing experiences from Egypt, France, India, Saudi Arabia and Thailand:

Amal El-Beshlawy (Egypt), Olivier Hermine (France), Alok Srivastava (India), Farrukh Shah (KSA), Vip Viprakasit (Thailand)

17.25 | 18.15

Discussion

18:15 | 18.30

NOVEL STRATEGIES FOR THE TREATMENT OF THALASSEMIA SYNDROMES

CHAIRPERSONS: Paolo Moi (Italy), Ali Taher (Lebanon)

SESSION VI

Highlights on gene therapy in haemoglobinopathies

Marina Cavazzana (France)

18.30 | 18.50

New pharmacological approches for increasing hemoglobin levels in Thalassemia Syndromes

Antonio Piga (Italy)

18:50 | 19.10

Conclusions

Aurelio Maggio (Italy)

19.10 | 19.30

Hepcidin and iron overload (NO CME)

Sponsored talk by La Jolla Pharmaceutical

Lakhmir S. Chawla (US)

19.30 | 19.45

(Simultaneous sessions) Panel discussion on RECOMMENDATIONS FOR INITIAL EVALUATION AND STAGING ASSESSMENT OF THALASSEMIA SYNDROMES

SESSION VII

PANEL I (Meeting Room: Aula Fici)

CHAIRPERSONS: Alan Cohen (US), Antonis Kattamis (Greece)

DISCUSSANTS: Marie-Charlotte Bouesseau; Marina Cavazzana, Gianluca Forni, Suthat Fucharoen, Olivier Hermine, Ansari Saqib Hussain, Mehran Karimi, Antonio Piga, John Porter, Paolo Ricchi, Farrukh Shah, Alok Srivatsava, Paul Telfer, Elliott Vichinsky, Vip Viprakasit

08.30 | 10.30

PANEL II (Meeting Room: Biblioteca)

CHAIRPERSONS: Amal El-Beshlawy (Egypt), Ali Taher (Lebanon)

DISCUSSANTS: Kunle Adekile, Yesim Aydinok, Caterina Borgna Pignatti, Maria Domenica Cappellini, Adriana Ceci, Shahina Daar, Vito Di Marco, Aldo Filosa, Mahmoud Hajipour, Ibrahim Hishamshah, Aurelio Maggio, Dudley Pennell, Alessia Pepe, Eliezer Rachmilewitz, Mahmoud Yassin

08.30 | 10.30

Coffee Break

10.30 | 10.45

PLENARY ROOM (Aula Magna “M.Vignola”)

CHAIRPERSONS: Aurelio Maggio (Italy), Ali Taher (Lebanon), Paul Telfer (UK), Elliott Vichinsky (US)

Presentation of Panel I – Recommendations for initial evaluation and staging assessment of Thalassemia Syndromes

Alan Cohen (US), Antonis Kattamis (Greece)

10.45 | 11.15

Presentation of Panel II – Recommendations for initial evaluation and staging assessment of Thalassemia Syndromes

Amal El-Beshlawy (Egypt), Ali Taher (Lebanon)

11.15 | 11.45

Discussion for general consensus on Presentations of Panel I and II

11.45 | 12.30

Final proposal and future strategy

Aurelio Maggio (Italy)

12.30 | 13.00

CME questionnaire

13.00 | 13.15

Closing remarks

Aurelio Maggio (Italy)

13.15 | 13.30

Light Lunch

13.30 | 14.30

Poster Session I on (NO CME)

THALASSEMIA MAJOR AND ANTIVIRAL TREATMENT, THALASSEMIA INTERMEDIA AND THE NEW ERA OF CHELATION TREATMENT

14.30 | 16.00

Poster Session II on (NO CME)

HIGHLIGHTS IN MANAGEMENT OF THALASSEMIA SYNDROMES IN EASTERN COUNTRIES, MRI AND CURRENT MANAGEMENT OF THALASSEMIA SYNDROMES AND NOVEL STRATEGIES FOR THE TREATMENT OF THALASSEMIA SYNDROMES

16.00 | 17.30

Conclusions

Aurelio Maggio (Italy)

17.30 | 17.45

Dr Marina Cavazzana

Pediatrician, Professor of Hematology since 2000, Director of the Department of Biotherapy at Necker Hospital, Paris Descartes University

Biography

MARINA CAVAZZANA is a pediatrician, Professor of Hematology since 2000, Director of the Department of Biotherapy at Necker Hospital, Paris Descartes University. She is the Director of the Inserm / Assistance Publique – Hôpitaux de Paris GHU Ouest Biotherapy Clinical Investigation Center and leads the research “Human lymphohematopoiesis” Laboratory at Imagine Institute.

Her main research and clinical interests are the development of the hematopoietic immune system, and cell and gene therapy for inherited and acquired disease of the hematopoietic system. Her group studies the means to improve the clinical results of hematopoietic stem cell transplantation, crossing HLA-barriers, and the differentiation of mouse and human stem cells towards lymphocyte lineages. She has initiated several clinical trials based on the use of ex vivo gene modified hematopoietic stem cells to treat patients with inherited disorders, the preliminary clinical results of which are encouraging. She is the author or co-author of one patent and of more than 270 publications in peer-reviewed journals and was awarded 2 ERC (2011 and 2016).

Dr Adriana Ceci

Gianni Benzi Pharmacological Research Foundation President

Biography

  • The role covered: Gianni Benzi Pharmacological Research Foundation President

Scientific Director of TEDDY- European Network of Excellence for paediatric clinical trials

  • current institution: Gianni Benzi Pharmacological Research Foundation
  • the number of scientific papers and the main topics : 127- Rare Diseases, Orphan Medicinal Products and Rare diseases, Thalassemia, Paediatric Medicines, Ethical and legal framework , Off-Label use
  • other positions in Scientific Societies or scientific journal: Member of SIP, SIRP, SIAR, SIF, (past-member AIEOP, AIOM)

Peer Reviewer of: EJof Clinical Pharmacology, EJ of paediatrics, EJH, Pediatrics, Journal of Pharmacy and Pharmacology, Pharmacoepidemiology and Drug Safety, Expert Opinion On Drug Safety.

Dr Alan Cohen

Professor of Pediatrics Children’s Hospital of Philadelphia

Biography

Alan R. Cohen, MD is Professor of Pediatrics at the Perelman School of Medicine, University of Pennsylvania (Penn) and the Children’s Hospital of Philadelphia (CHOP), Philadelphia, PA, USA. After earning his BA degree from Harvard College and his MD degree from Penn in 1972, Dr Cohen completed his internship and residency at CHOP in 1974. He was Chief Resident from 1974 to 1975, and held a hematology-oncology fellowship at CHOP from 1975 to 1978. He was appointed as Assistant Professor of Pediatrics at Penn in 1978 and promoted to Associate Professor in 1984 and to Professor in 1990. From 1992 until 2001, he was Chief of the Division of Hematology at CHOP. In 2001, he was appointed as the Chair of the Department of Pediatrics and Physician-in-Chief at CHOP and Penn, and he completed 12 years in these positions.

Professor Cohen’s research interests have focused on thalassemia, sickle cell disease, and transfusional iron overload. He has developed novel approaches to transfusion therapy to reduce the rate of iron accumulation, and has led clinical trials of the currently licensed iron chelators.

Among his more than 100 publications are original papers in major journals such as the New England Journal of Medicine, Blood, The Lancet, the British Journal of Haematology, and the Journal of Pediatrics. Professor Cohen was the Chair of the Seventh Cooley’s Anemia Symposium of the New York Academy of Sciences, and he served as editor of the subsequent volume of the Academy’s Annals. He has been a co-editor of the international guidelines for the management of thalassemia, and a volume on iron disorders for the Hematology/Oncology Clinics of North America. He has been awarded numerous research grants from the National Institutes of Health (NIH) and the Centers of Disease Control and Prevention (CDC).

Professor Cohen has served as Chair of the Board of Directors of the American Board of Pediatrics, as President of the Association of Medical School Pediatric Department Chairs (AMSPDC) and the American Society of Pediatric Hematology/Oncology (ASPHO), and as Chair of the Medical Advisory Board of the Cooley’s Anemia Foundation.

Dr Shahina Daar

Department of Haematology, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman (retired)

Biography

 

Shahina Daar is a recently retired Professor in the Department of Haematology at the College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman. She has directed the Thalassaemia Unit at the Sultan Qaboos University Hospital for 26 years; this is the largest centre of its kind in Oman and serves as a referral centre for the entire country.

Dr Amal El-Beshlawy

Biography

 She was graduated from Cairo University (with the degree of honor) and where she did all her academic career. She was the founder and president of the Pediatric Hematology Department from 1984 till 2005, Emirate professor and senior consultant till present. She received her training in pediatric hematology and bone marrow transplantation in Necker Hospital Paris, France in 1978-1979. She is the founder and the president of the ” Egyptian Thalassemia Association (ETA)” since 1990. ETA is a member of the Thalassemia International Federation (TIF) in 1992. Prof. El-Beshlawy has been awarded the “Prize of the state for Excellence in Medical Sciences” (mainly thalassemia) in 2002, the Prize of “Cairo University in Medicine” in 2005 and the Priz of “ Distinction in Medicine in 2008”. Sultan Bin Khalifa International Thalassemia Award from UAE for Best Research in 2015. She is a member of the National Committees for Blood Diseases in Pediatrics, for Thalassemia Centers Estalishment and for Blood Diseases Therapeutics Evaluation and Registration by A Ministerial Decree in 2007.

She is the principal supervisor for more than 114 MD & MSc. Thesis mostly on Thalassemia The Principal Investigator (PI)of Twenty Five International Projects mostly on Thalassemia, (iron chelators researches), on Hemophilia and Gaucher Disease. She is a member of the International Steering Committee and Speaker Bureau since 2004 for known International Therapeutic Companies for treatment of thalassemia The Egyptian partner for Three European Commission (EC) Projects for thalassemia” ITHANET, MedGenet & DEEP” form 2006 till present. She has been an invited speaker for more than 80 International Conferences and Workshops on thalassemia (mainly), on Gaucher Disease and Hemophilia.

Prof. El-Beshlawy authored and co-authored more than 120 International publications on thalassemia (mainly) and others on hemophilia and Gaucher disease published in high impact peer reviewed Journals including: New England Journal of Medicine (NEGM) ,Blood , Hematologica and others.

She is a member of: the International Society of Hematology (ISH) since 1988 and its Egyptian consoler from 2004. Secretary of ISH conference in 2002 and President of the conference in 2009.Member of TIF in 1992 and its scientific collaborator since 2002. MEMBER of: The European Hematology Association (EHA) since 1994, The American Society of Hematology(ASH) since 2007. EDITOR: for the “Journal of The American Medical Association (JAMA) Pediatrics Middle East” from 1998, The World Journal of Medical Science in 2012 and Red Cell Molecules and Diseases Journal in 2014.

Dr Aldo Filosa

Director of Rare Red blood cell diseases Unit

Biography

Director of Rare Red blood cell diseases Unit – UOSD Centro per le Microcitemie , A.O. Antonio Cardarelli

Dr Suthat Fucharoen

Thalassemia Research Center Institute of Science and Technology for Research and Development, Mahidol University, Salaya Campus

Biography

Dr. Suthat Fuchareon is Professor Emeritus at the Institute of Molecular Biosciences, and Director of the Thalassemia Research Center, Mahidol University, Nakornpathom, Thailand.
Dr. Fuchareon is internationally recognized for his work on thalassemia in Thailand and Southeast Asia. His scientific interests encompass the spectrum of basic, translational, clinical and epidemiological research. Work from the Thalassemia Research Center at Mahidol University has set the standard for defining the molecular genetics, genomics, and genotypic/phenotypic correlations of thalassemic syndromes. His many publications include clinical trials on the use of inducers of fetal hemoglobin and iron chelation, the use of MRI imaging for assessment of iron overload, as well as landmark epidemiologic studies defining the genetic diversity and public health burden of these diseases.
Dr. Fuchareon has been the recipient of many honors, among them the Outstanding Researcher Award from the National Research Council of Thailand, Outstanding Scientist Award from the Foundation for the Promotion of Science Award and Technology under the Patronage of His Majesty the King of Thailand. Dr. Fuchareon had delivered the Berend Houwen Lecture at the International Society for Laboratory Hematology in New Orleans on May 6, 2011

Dr Mehran Karimi

Professor of Pediatric Hematology OncologyMedical Director of Hematology Research Center Shiraz, Iran

Biography

  • The role you covered: Preordered interventions, which is the state of art in transfusion safety and anti-viral treatment of thalassemia syndrome; an Iranian experiences
  • Your current institution: Medical Director of Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
  • The number of your scientific papers and the main topics discussed: I published more than 300 scientific papers more focusing on thalassemia, thrombosis and coagulation disorders. My main topic in this meeting is Iranian experiences on transfusion safety and anti-viral treatment of thalassemia syndrome
  • Other positions in Scientific Societies or scientific journal: I am advisory consultant at TIF, member of ISTH, ASH and I-CET and peer reviewer of many scientific hematology journals (All are included in my CV)

 

Thanks

Mehran Karimi

Professor of Pediatric Hematology Oncology

Medical Director of Hematology Research Center

Shiraz, Iran

Dr Antonis Kattamis

National and Kapodistrian University of Athens

Biography

• The role: Session Chair; Conference Invited Chair
• current institution : National and Kapodistrian University of Athens
• the number of scientific papers and the main topics discussed: 100 mainly on hemoglobinopathies and iron chelation
• other positions in Scientific Societies or scientific journal:

Hellenic Society of Pediatric Hematology-Oncology (Council Member) Central National Counseling Health Board on Thalassemia (President) European Society of Paediatric Haematology Immunology, (Secretary) European Journal of Haematology (Associate Editor)

Dr Aurelio Maggio

Director of Department of Hematology II of Hospital “Villa Sofia Cervello” Palermo; Director of Department of Hematology and Oncology, “V.Cervello” Hospital, Palermo

Biography

Director of Department of Hematology II of Hospital “Villa Sofia Cervello” Palermo; Director of Department of Hematology and Oncology, “V.Cervello” Hospital, Palermo

Dr Paolo Moi

Associate Professor of Pediatrics

Biography

Paolo Moi, MD

Associate Professor of Pediatrics

Director of Pediatric Clinic, Thalassemia and Rare Diseases AOB Cagliari

  • Department of Biomedical Sciences and Public Health

University of Cagliari

  • Author of 58 peer reviewed papers

Main topics: Thalassemias, Globin Gene Regulation, Gene Therapy of Hemoglobinopathies

  • other positions in Scientific Societies or scientific journal

Khaled Musallam

President, International Network of HematologyCenter

Biography

President, International Network of Hematology

170 pee-reviewed articles – on hemoglobinopathies, other congenital and acquired anemias, thrombosis/hemostasis

Dr Antonio Piga

Professor of Pediatrics and Dean of the School of Medicine at S. Luigi University Hospital of Torino UniversityFaculty Member

Biography

Antonio Piga is Professor of Pediatrics and Dean of the School of Medicine at S. Luigi University Hospital of Torino University.

He developed and leads the reference Centre for Hemoglobinopathies, endorsed by Italian Ministry of Health and European Rare Diseases Network.

His research activities are focused on novel diagnostic and therapeutic approaches for thalassemia and iron overload, academic teaching and medical librarianship. He is author of more than 180 scientific publications in peer-reviewed journals.

Dr Paolo Ricchi

Assistant at Unit of Rare Red Cell Disease of AORN Cardarelli, Naples, Italy

Biography

Current position: Assistant at Unit of Rare Red Cell Disease of AORN Cardarelli, Naples, Italy

He published more than 50 scientific full articles in peer reviewed international journals

(23 as first author and 3 as last author)

h-index = 15 Number of citations = 913 ( Google scholar)

Main research fields:

As oncologist: Antineoplastic agent, chemoprevention and genito-urinary cancers.

As hematologist: Thalassemia and hemoglobinopathies:

1) Hepatitis treatments and liver cancer in thalassemia.

2) Extramedullary hematopoiesis, incidental findings and malignancies in thalassemia

3) the combined modality of iron chelation in thalassemia major patients

4) NTDT: pathogenesis and complications

5) The role of the soluble form of the transferrin receptor as biomarker of disease severity

6) new hemoglobin inducers.

He is a sub investigator in the ongoing, phase 2, multicenter, open-label, dose-finding study followed by a long-term extension study to evaluate the effects of luspatercept in patients with either transfusion-dependent (TD) or non-transfusion dependent (NTD) beta-thalassemia

He is also a sub-investigator in the ongoing Phase 3, double bind, randomized, placebo-controlled, multicenter study of Luspatercept versus placebo in adults who require regular red blood cell transfusions due to B-Thalassemia (BELIEVE).

Since 2015 is a Member of the Scientific Committee of E-Myocardial Iron Overload (E-MIOT) Network

Dr Vip Viprakasit

Division of Paediatric Haematology / Oncology
Department of Paediatrics and Thalassaemia Centre
Siriraj Hospital, Mahidol University
Bangkok Thailand

Biography

Vip Viprakasit is a Professor of Pediatrics at Department of Pediatrics & Thalassemia Center at Siriraj Hospital, Mahidol University, Bangkok, Thailand. He received his MD with 1st class honor in 1987 from the first medical school in Thailand; Siriraj hospital, Mahidol University and then trained as a pediatrician and pediatric hematologist in Royal College of Pediatrics, Thailand. He then continued his training in the UK and got his DPhil from University of Oxford in 2002 and finished his postdoctoral fellowship in molecular hematology at Weatheral Institute of Molecular Medicine with Prof. Douglas R. Higgs, FRS in 2004. He then returned back to Mahidol University where he was the appointed as a faculty at Department of Pediatrics, Siriraj hospital and became a full Professor in 2015. His major research focus has been on a translational medicine to bridging between basic molecular biology to routine clinical practice in hematology. Using the most common inherited disease in the Asian population; thalassemia as his model, he has extensively studied this condition in several aspects including molecular basis, pathophysiology, genotype-phenotype correlation, molecular diagnosis from routine service to pre-implantation genetic analysis to non-invasive prenatal test and newborn screening. From these fundamental works, he has expanded his works into molecular basis, clinical management and developing clinical and laboratory tools for iron overload and iron deficiency anemia, both are prevalent in his region and representing two important problems in developing world. Dr. Viprakasit has served as an Associate Editor of Blood Research, Journal Medical Association of Thailand, Southeast Asian Journal of Tropical Medicine & Public Health and a member of steering committee for Nanotechnology Institute of Thailand and numerous clinical trials for pharmaceutical companies related to iron dysregulation in man. He received the best research award of the year in 2016 from The National Research Council of Thailand and a Sultan Bin Khalifa Award from UAE for the Excellent Center for Thalassemia Care under his supervision in 2014. Although working and researching in a resource limited setting like Thailand, Dr. Viprakasit has authored or co-authored more than 150 peer-reviewed publications in less than 15 years, and has written many reviews on thalassemia and/or iron related complications as well as chapters in major hematology reviews for American Society of Hematology (ASH) and European Hematology Association (EHA).

 

Dr Eliezer Rachmilewitz

Hematology Department Edith Wolfson Medical Center Holon, Israel

Biography

Prof. Eliezer Rachmilewitz was born in Jerusalem. His father, Prof. Moshe Rachmilewitz was one of the founders of modern medicine in the State of Israel.

Prof. Rachmilewitz received all his medical education in Israel and was the Head of the Hematology department in Hadassah Hospital in Jerusalem for 20 years. From 2000 to 2012, he was the Head of the Hematology department in Wolfson Hospital in Holon. He is continuing to work as a consultant in Wolfson Hospital and in Assuta Medical Center. He is also an adjunct professor of Medicine in New York Cornell University Presbyterian Hospital.

In 2013, he was appointed as the head of medical policy division in the Israeli Medical Association.

During this period of time, Prof. Rachmilewitz was very active in the local as well as in the international medical community. His reputation all over the world brought into practice new therapeutic treatments to the State of Israel. Numerous patients from all over Israel and neighboring countries seeking advanced medical care have sought his consultation.

Prof. Rachmilewitz has excelled not only in patient care but has also matured a new generation of young hematologists who are at the forefront of the hematological community in nearly every hospital in Israel and abroad, from the Palestinian Authority to Ethiopia and in the United States.

He has 301 publications and 3 papers in preparation.

His main area of research evolves around the pathophysiology of thalassemia, a disease which is highly prevalent in the Middle East and South East Asia. He and his colleagues described for the first time the presence of non transferrin bound iron (NTBI) in thalassemia which is recognized as a catalyst in the formation of oxygen free radicals and generating increased oxidative stress.

He initiated the first study that showed low hepcidin levels in thalassemic mice that explained their increased iron absorption.

Another new finding is on decrease in the levels of Hemopexin, a protein that binds excess of heme in multitransfused patients with thalassemia.

Another area that he was one of the first to explore is Hypercoagulable State in Hemoglobinopathies. His first review on this topic was published in Blood together with his late colleague Dr. Amiram Eldor in 2002! He has been involved in the study of multiple asymptomatic ischemic lesions in the brain of patients with thalassemia.

His most recent work is the finding of increased level of Heparanase, a procoagulant enzyme, in multitransfused patients with thalassemia.

In September 2005 he published a progress report on thalassemia in the New England Journal of Medicine, and in 2011 on “How I Treat Thalassemia” in Blood.

He is considered as one of the world experts in this disease and is invited all over the world to present the results of his work.

As an extension of studies in thalassemia, he recently became interested in the role of oxidative stress in congenital and acquired hemolytic anemias and particularly in iron overload in Myelodysplastic Syndrome (MDS), which is a relatively new area. One of his recent reviews on the impact of iron overload in low risk myelodysplastic syndrome was published in Blood in 2014.

Consequently, he is studying how the potential risks of oxidative damage on transformation to Leukemia and whether it can be prevented by iron chelators and/or antioxidants.

One of his recent studies is to measure iron deposition by T2* MRI in patients undergoing dialysis who receive a lot of iron, which is deposited in major organs. A review on this subject has appeared in Nephrology, Dialysis and Transplantation.

He is one of the most prominent physicians in Israel and one of the 3 official physicians of the Prime Minister.

He was a host of a popular weekly television program on Health issues, where he interviewed experts from all fields of medicine for more than 10 years.

He was a co-chairman of an international meeting on controversies in Hematology. The first meeting was in Rome in 2010, the second was in Barcelona in 2012, and the 3rd one took place in Istanbul in 2014.

He is married for the second time to Tova, who is an artist, a father of 3 children and 11 grand-children.

 

Dr Santina Acuto

Unità di Ricerca “P.Cutino”, U.O.C. Ematologia e Malattie Rare del Sangue e degli Organi Ematopoietici
A. O. Ospedali Riuniti Villa Sofia – Cervello

Biography

Responsabile di Ricerca : coordina un gruppo di biologi e biotecnologi contrattisti.
Area di Ricerca: Design e creazione di vettori lenti virali ricombinanti per il gene della beta- globina umana e per sequenze genomiche responsabili

dell’efficacia e della sicurezza dei vettori per terapia genica in cellule Staminali Ematopoietiche(CSE). Studi di efficienza, efficacia terapeutica e genotossicità di vettori lenti virali in linee cellulari ematopoietiche umane e murine ed in cellule staminali ematopoietiche umane. Studio funzionale di vettori retro-virali fiancheggiati da elementi di DNA con funzione di isolatori cromatinici. Manipolazione cellulare: Espansione ex-vivo di CSE e modificazione genetica con vettori lentivirali. Ottimizzazione delle condizioni per la manipolazione ex-vivo delle CSE e studi in-vitro ed in- vivo degli aspetti di staminalità e differenziamento dopo manipolazione. Area della Formazione : dal 2004 Incarico aziendale di gestione scientifico-organizzativa per lo svolgimento del tirocinio formativo pre – laurea e postlaurea (Facoltà di Scienze Biologiche e Facoltà di Biotecnologia, Facoltà di Medicina, corso specialistico di Biotecnologie Mediche e Medicina Molecolare), come da Convenzioni stipulate tra l’Azienda e l’Università degli Studi di Palermo,

Ad oggi tutore e componente di commissione di laurea di :
-N° 16 tesi di laurea nelle Facoltà di Scienze Biologiche e Biotecnologia della Università degli Studi di Palermo
-N° 6 tesi di specializzazioni post laurea (Dottorati di Ricerca e di Scuole di Specializzazione).

Dr Elena Baiamonte

Term-contract as Researcher with experience in cell biology
Hematology and rare blood diseases division of Ospedali Riuniti Villa Sofia Cervello Hospital, Palermo, Italy.Faculty Member

Biography

Term-contract worker

Dr Valentina Cigna

Medico Specialista in Ostetricia e Ginecologia esperto in Medicina Fetale e Diagnosi PrenataleFaculty Member

Biography

Competenze :

– Diagnostica prenatale invasiva ( amniocentesi, villocentesi , cordocentesi, celocentesi, IVG selettive )

– Terapia intrauterina ( amniodrenaggio, toracentesi fetale, paracentesi fetale ) in qualità di I e\o II operatore.

– Diagnostica prenatale non invasiva : ecografie ostetriche di I e II livello, flussimetria doppler dei vasi feto-placentari

– Gestione di gravidanze a rischio : per patologia cromosomica, malattie genetiche, malformazioni fetale, ritardi di crescita uterini, anemia emolitica fetale, infezioni intrauterine, gravidanze gemellari

Dr Francesca Damiani

Dirigente Medico di Ostetricia e Ginecologia

I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Dr Rosario Di Maggio

Department of Thalassemia and rare Haemoglobinopathies, Ospedali Riuniti Villa Sofia-Cervello, Palermo

Biography

Coordinate and Continous Collaboration project “ Istituzione di una biobanca per ovociti e tessuto ovarico per la tutela della funzione riproduttiva in paziente affetti da malattie neoplastiche e degenerative”

Dr Rosalia Di Stefano

Term-contract as Researcher with experience in cell biology

Biography

Term-contract as Researcher with experience in cell biology                    

Dr Manuela Fecarotta

UOC Ematologia 2 , AOR Villa Sofia-Cervello, Palermo

Biography

L’attività scientifica della Dott.ssa Emanuela Fecarotta si è tradotta nelle pubblicazioni di n. 26 lavori in esteso e n. 38 abstacts pubblicati sia su riviste nazionali che internazionali Impact factor 66,84 , H.Index 10 (Scopus)

Dr Antonino Giangreco

Dirigente Medico attualmente in servizio presso Ematologia 2 e Malattie Rare del Sangue e degli Organi ematopoietici del P.O. V. Cervello

Dirigente Medico attualmente in servizio presso Ematologia 2 e Malattie Rare del Sangue e degli Organi ematopoietici del P.O. V. Cervello,

Si occupa della prevenzione e screening della talassemia e delle emoglobinopatie;

della gestione e del follow-up dei pazienti con emoglobinopatie ed anemie croniche (ad es. Talassemia intermedia, Talassemia Major e anemia falciforme).

Svolge la propria attività per i pazienti in regime ambulatoriale, in regime di Day-Hospital e in regime di ricovero ordinario.

Dr Florinda Listì

Biologa

Biography

Ha acquisito competenze nei settori di: Tipizzazione tissutale (sierologica e molecolare), Biologia cellulare (colture di cellule in vitro, test di citotossicità e di induzione farmacologica di HbF), Biologia Molecolare ( estrazione del DNA da sangue periferico ed RNA, tecniche di PCR di base, Real time e sequenziamento), Ematologia (strisci di sangue periferico, emocromo), Chimica Clinica, Citofluorimetria, Immunoematologia, Autoimmunità e Batteriologia.

  • Dr Melania Lo Iacono

    Term-contract as Researcher with experience in molecular
    diagnosis of hematological rare diseases Hematology and rare blood diseases division of Ospedali Riuniti Villa Sofia- Cervello Hospital, Palermo, Italy.Faculty Member

Biography

Excellent organizational and interpersonal skills acquired during different workshops organized at the Department of Experimental Biomedicine and Clinical Neurosciences, Section of Human Anatomy , University of Palermo .

Excellent interpersonal skills with students acquired during laboratories organized for students of the faculty of Medicine, of University of Palermo, at the Department of Experimental Biomedicine and Clinical Neurosciences , Section of Human Anatomy.

Skills in the use electrophoretic techniques: (proteins and DNA extraction kit), thermal cycler, incubator, spectrophotometer, tools for cell culture (laminar flow hood, centrifuges, chamber Burker). Techniques acquired: immunohistochemistry , immucitochemistry, histological staining, protein extraction, Western blotting, DNA and RNA extraction, PCR, RealTime-PCR and RT–PCR,, southern blotting, RFLP analysis with restriction enzymes, two-dimentional electrophoresis, mixed lymphocyte reaction, flow cytometry analysis, transduction, lentiviral preparation, real-time PCR.

Cell culture: isolation and characterization of umbilical cord-derived mesenchymal stem cells. Several differentiation protocol toward hepatic-like phenotype, adipocyte-like, osteocyte-like, chondrocyte-like phenotype. isolation of hematopoietic stem cells, isolation and separation of CD34+ cells by magnetic beads (Miltenyi), flow cytometry analysis by ISHAGE methods, colony forming unit assay, real time- PCR, preparation of lentiviral vector.

Dr Salvatore Madonia

Dirigente Medico di primo livello presso la Divisione di Medicina P.O. V.Cervello della Azienda Ospedaliera “Villa Sofia-Cervello”, Palermo

Biography

Laurea in Medicina e Chirurgia conseguita a Palermo il 12/07/84 con voti 110/110 e lode; candidatura al premio “Albanese” con tesi sperimentale dal titolo “Emorragie digestive dei cirrotici: fattori di rischio e tentativi di prevenzione”.

Abilitazione all’esercizio della professione medica conseguita a Palermo nella Seconda Sessione 1984 con voti 120/120.

Iscrizione all’Ordine dei Medici della provincia di Palermo dal 29/01/85, numero 9003

Specializzazione in “Medicina Interna” presso la seconda scuola di specializzazione in Medicina Interna dell’Università’ di Palermo, dir. Prof. G.D.Bompiani, in data 11/12/89, con voti 50/50 e lode, con tesi sperimentale dal titolo “La scleroterapia delle varici esofagee nella cirrosi epatica”.

Specializzazione in “Malattie dell’apparato digerente” presso la scuola di Specializzazione dell’Università di Palermo, dir. Prof. L.Pagliaro, in data 28/12/93, con voti 50/50 e lode con tesi sperimentale dal titolo “Scleroterapia delle varici esofagee: verso il protocollo ottimale?” frutto di uno studio durato 11 anni che ha coinvolto 398 pazienti per un periodo medio di 60 mesi.

Luigi Mancuso

Consultant of Cardiology and EchoDoppler of Cervello Hospital Palermo( Italy) and Candela Clinic Palermo ( Italy ).

Date of bearth 06 07 1941

2009 to present : Consultant of Cardiology and EchoDoppler of Cervello Hospital Palermo( Italy) and Candela Clinic Palermo ( Italy ).

1970-2008 Department of Cardiology Cervello Hospital Palermo. Responsible for the Department of Noninvasive Cardiology.

1980-2004 Principal Investigator in 6 Research Studies supported by the Assessorato Sanità Regione Sicilia.

1965 MD with honour , distinction and mention in Medicine and Surgery Palermo University. Italy

1967 Full Board in Gastroenterology and Liver Diseases. 1970 Full Board in Internal Medicine with honour
1972 Full Board in Cardiovascular Diseases.

1980 – 9 SIEC Certification as Tutor of Specialization in Echocardiography and Doppler.

Stages:
University of Milano ( Italy)
S. Camillo Hospital Roma ( Italy ) Trondheim University ( Norway ) Mayo Clinic ( Rochester, USA ) Onassis Centre ( Athene, Greece )

Publications ( total number 80 ).
Madre lingua : Italiano
Buona conoscenza della lingua inglese ( comprensione, parlato, scritto ) Discreta conoscenza di francese e spagnolo

Nunzio Minniti

Biologo Dirigente c/o Azienda Ospedaliera Villa Sofia – Cervello, Centro Inter-Aziendale di PMA.

Biography

Consulente Scientifico c/o: Centro Procreazioni Assistite Demetra (PAD) e Centro PMA A.S.T.E.R., c/o Clinica del Mediterraneo.

Biologo Dirigente c/o Azienda Ospedaliera VILLA SOFIA – CERVELLO, Centro Inter-Aziendale di PMA.

Emanuela Orlandi

Attività libero professionale di Ostetricia e Ginecologia presso Centro di Diagnosi Prenatale

Biography

Attività libero professionale di Ostetricia e Ginecologia presso il Centro, eseguendo un numero difficilmente calcolabile (trattandosi di migliaia) di ecografie ostetriche morfologiche di I e II livello, più di 3000 screening bichimici ed ecografici delle aneuploidie del primo trimestre, 4900 screening delle cardiopatie nel I trimestre di gravidanza, più di mille ecocardiografie fetali nel II trimestre di gestazione, amniocentesi e villocentesi.

Dr Alice Pecoraro

Researcher Biologist at the Campus of Haematology “Franco e Piera Cutino” – A.O.O.R. “Villa Sofia – Cervello” in Palermo

Biography

Dr Alice Pecoraro is a Researcher Biologist at the Campus of Haematology “Franco e Piera Cutino” – A.O.O.R. “Villa Sofia – Cervello” in Palermo. She obtained her degree in Biological Sciences (five year programme-Biomolecular) in 2001 and subsequently her PhD in Cell Biology (Cell and developmental Biology) in 2005 at the University of Palermo. There she continued her postgraduate studies, specialising in Clinical Biochemistry in 2010.
Since 2006 she was involved in several research project focused on gene and pharmacological approaches for the treatment of sickle cell disease and beta-thalassemia developing noteworthy skill and expertise on globin gene expression, primary erythroid cultures and flow cytometric analysis. In particular her research focused on the study on hydroxyurea mechanism of action and on the response of haematopoietic precursors from patients with hemoglobinopathies to pharmacological agents inducers of fetal haemoglobin production. She cooperated to develop an ex vivo system predictive of the in vivo response of patients to hydroxyurea treatment.
She currently works also on cellular and molecular diagnosis of numerous rare genetic disease at the Laboratory of Molecular Genetics of the U.O.C. Haematology for Rare Diseases of blood and Haematopoietic Organs.
She is co-authored of several peer-reviewed papers.

Dr Lorella Pitrolo

Investigatore principale o coinvestigatore in progetti di ricerca sanitaria regionale per la prevenzione e cura della talassemia

Investigatore principale o coinvestigatore in progetti di ricerca sanitaria regionale per la prevenzione e cura della talassemia
Esperienza in trials clinici condotti in accordo con le GCP
Investigatore principale o coinvestigatore in studi multicentrici nazionali ed internazionali riguardanti i seguenti campi:
• Sperimentazioni farmacologiche :chelazione del ferro, osteoporosi
• Valutazione accumulo marziale mediante Metodica RMT2*
• Aspetti psico-sociali delle talassemie
• Valutazione efficacia e sicurezza nuovi protocolli terapeutici sulla ferrochelazione

Dr Maria Concetta Renda

Dirigente biologo, Unità Operativa Complessa di Ematologia per le Malattie Rare del Sangue e degli Organi Ematopoietici, A.O.R. Villa Sofia-Cervello (ex A.O. “Vincenzo Cervello) Palermo

Biography

Novembre 1991-Specializzazione in Patologia Generale Facoltà di Medicina e Chirurgia, Università degli Studi di Catania (votazione 50/50 e lode)
Aprile 1985- Abilitazione all’esercizio professionale di Biologo e iscrizione all’Albo dell’Ordine Nazionale dei Biologi
Febbraio 1984- Diploma di laurea Facoltà di Scienze Biologiche, Università degli studi di Palermo (votazione 110/110 e lode) Luglio 1979 Maturità Scientifica con voti 60/60

Dal Marzo 1991 a tutt’oggi Dirigente biologo, Unità Operativa Complessa di Ematologia per le Malattie Rare del Sangue e degli Organi Ematopoietici, A.O.R. Villa Sofia-Cervello (ex A.O. “Vincenzo Cervello) Palermo
1986-1991 Borsa di studio Assessorato Regionale alla Sanità Progetto di Ricerca Finalizzata. Borsa di studio annuale Progetto Obiettivo Regionale “Prevenzione,Cura e Riabilitazione delle Malattie Ematiche”. Borsa di studio biennale del CNR

Dr Giovanna Schillaci

Medico Specialista in Ostetricia e Ginecologia esperto in Medicina Fetale e Diagnosi Prenatale

Biography

Medico Specialista in Ostetricia e Ginecologia esperto in Medicina Fetale e Diagnosi Prenatale

AOOR VILLA SOFIA CERVELLO, PALERMO (Italia)

Competenze :

– Diagnostica prenatale invasiva ( amniocentesi, villocentesi , cordocentesi, celocentesi, IVG selettive )

– Terapia intrauterina ( amniodrenaggio, toracentesi fetale, paracentesi fetale ) in qualità di I e\o II operatore.

– Diagnostica prenatale non invasiva : ecografie ostetriche di I e II livello, flussimetria doppler dei vasi feto-placentari

– Gestione di gravidanze a rischio : per patologia cromosomica, malattie genetiche, malformazioni fetale, ritardi di crescita uterini, anemia emolitica fetale, infezioni intrauterine, gravidanze gemellari

Dr Rosaria Schillaci

Dirigente biologo, con l’ incarico di Responsabile del Laboratorio Interaziendale (ASP PA, AOU Policlinico, AOR Villa Sofia-Cervello) di III° livello di Procreazione Medicalmente Assistita.

Biography

Attualmente svolge la propria attività presso l’Azienda Ospedali Riuniti Villa Sofia- Cervello di Palermo nella divisione ginecologica, con qualifica di Dirigente biologo, con l’ incarico di Responsabile del Laboratorio Interaziendale (ASP PA, AOU Policlinico, AOR Villa Sofia-Cervello) di III° livello di Procreazione Medicalmente Assistita.

Laurea in Scienze Biologiche con Lode conseguita il 16/02/1986 discutendo una tesi sperimentale dal titolo: “Modificazioni dello stroma nella carcinogenesi – Studi sul carcinoma duttale infiltrante di mammella umana”. La tesi e’ risultata vincitrice del premio Angela Rotolo 1987, bandito dall’ Università degli Studi di Palermo, quale migliore tesi nel campo dell’eziologia, della patogenesi e della chemioterapia dei tumori.

Dr Serena Sclafani

Biologa

Biography

Dopo un breve periodo (2006-2007) in cui mi sono occupata di controllo della filiera alimentare nell’ambito del progetto “Applicazioni di microtecnologie avanzate in campo chimico-biologico per il controllo dei prodotti della filiera agro-alimentare” presso il CRES di Monreale, dal 2008 ad oggi lavoro presso l’ U. O. C. “Malattie rare del sangue e degli organi ematopoietici” diretta dal prof. Aurelio Maggio nel gruppo della dottoressa E. D’Alcamo all’interno del quale mi sono occupata di:

  •   Diagnosi molecolare e diagnosi prenatale di Fibrosi Cistica con tecniche di biologia molecolare (Reverse dot blot, sequenziamento, restrizione enzimatica, estrazione di DNA e RNA da cellule e tessuti)
  •   Diagnosi differenziale di anemie emolitiche rare su base genetica (sferocitosi, ellissocitosi, CDAs, stomatocitosi) con test di base e di II livello come striscio di vetrini, test di resistenza osmotica, test citofluorimetrici, estrazione e quantificazione proteine di membrana del globulo rosso, analisi e sequenziamento di geni
  •   Diagnosi e studi di segregazione di geni coinvolti nella patogenesi di distrofie retiniche con tecniche di sequenziamento classiche e NGS (next generatyion sequencing)
  •   Consultazione dei principali database, piattaforme bioinformatiche, programmi di predizione di folding di proteina (Pubmed, dbSNP, Ensembl, Polyphen, Clinvar, Retnet, Orphanet)
  • Dr Riccardo Volpes

    Chief of Hepatology and Gastroenterology – Istituto Mediterraneo dei Trapianti e delle Terapie ad Alta Specializzazione (ISMETT-IRCCS) – Palermo. Associate Professor of Medicine at the Department of Medicine, UPMC (University of Pittsburg Medical Center), Pittsburgh, USA.Faculty Member

Biography

Senior Attending in Hepatology and Gastroenterology – Hepatology Unit – Department of Medicine – Istituto Mediterraneo dei Trapianti e delle Terapie ad Alta Specializzazione (ISMETT) – Palermo.

Associate Professor of Medicine at the Department of Medicine, UPMC (University of Pittsburg Medical Center), Pittsburgh, USA.

Chief of Hepatology and Gastroenterology – Istituto Mediterraneo dei Trapianti e delle Terapie ad Alta Specializzazione (ISMETT-IRCCS) – Palermo. Associate Professor of Medicine at the Department of Medicine, UPMC (University of Pittsburg Medical Center), Pittsburgh, USA.

Dr Timothy Guy St. Pierre

Professor, School of Physics, The University of Western Australia – Chief Scientific Officer, Resonance Health Ltd

Biography

Australian Academy of Technological Sciences and Engineering – Clunies-Ross Award 2010 IEEE Magnetics Society – Distinguished Lecturer 2014
Thalassaemia International Federation – Panos Englezos Prize 2016

Dr Stefano Frediani

Product Manager Italy HPLC HPLC ( HbA1c and Thalassemia)

  1. Complex selling activities, contract procedures, negotiations and tenders. WS/Demo activities, organization and managing on the field.
    Scientific articles promotion.
    Scientific events organization.New line/product launching.

Dr Soteroula Christou

Superior Medical Officer, Administrator, Nicosia Thalassaemia Centre, Archbishop Makarios III Hospital

I am a clinician and the Superior Medical Officer/Administrator of the Nicosia Thalassaemia Centre at the Archbishop Makarios III Hospital. I have extensive experience, for 26 years, in the clinical management of haemoglobinopathies. I oversee all aspects of care for patients with β-thalassaemia, haemoglobin H disease, and heterozygous and homozygous individuals bearing variant haemoglobins. I participate in a number of research projects. My main research interest include chelation therapy, gene therapy for thalassaemia, genotype/phenotype correlations , treatment of osteoporosis. Education activities include training and teaching to medical students and other health professionals in the field of haemoglobinopathies.

Dr Stefaan Marivoet

Manger Clinical Affairs Tosoh Europe N.V

Master in Biological sciences at the University of Leuven (Belgium)

PhD in Biological sciences at the department of sciences of university of Leuven (Belgium):

Main topic of research: identification of neuropeptides in the hypothalamus/hypophyseal system of the vertebrates

Post-doctoral research at the department of medicine at the University of Leuven (Belgium):

Main topic of research: Interaction of the androgen receptor with other proteins and especially with hsp90.

Manager Clinical Affairs at Tosoh Europe NV: Responsible for scientific and clinical support of the customers for the vitro diagnostic products distributed by Tosoh in Europe Middle east and Africa.

Letter to the Faculty

Dear all,

Thank you very much for accepting to join the International Working Group (IWG) on Thalassemia.

The main aim for establishing this IWG is to revisit the conventional thalassemia classification of severity (Thalassemia Major and Intermedia), owing to recent evidence suggesting the dichotomy may not be as distinct and in view of recent changes in patient management and identification of phenotypes based on transfusion-requirement.

In order to do that, we would need first to reach a consensus on the key factors to consider for such a revision, through a standard methodology and evidence grading system (e.g. GRADE by Guya et al., 2008). In this context, some thoughts to consider for defining disease severity through a new model, subject to discussion during the meeting, would be:

1) The quality/grade of evidence for the currently used criteria to differentiate thalassemia major versus intermedia at initial diagnosis:

  • age of diagnosis (<2 vs >2 years old)

  • Hemoglobin level (<7 vs >7 g/dl)

  • growth failure (<3 percentile)

  • Hemoglobin electrophoresis results

2) The risks versus benefits of including patients in transfusional regimens independent of age and hemoglobin level at onset of the disease, with periodical re-evaluation

3) The quality/grade of evidence for the currently used criteria to start iron chelation therapy

  • age (2 years or older )
  • transfusions (10-20 tx)

  • serum ferritin level (> 1000 ng/mL)

  • LIC >7 mg Fe/g (with age-related assessment limitations)

4) The wide spectrum of disease severity in patients currently labelled as thalassemia intermedia, with respect to pathogenesis and clinical complications profile.

We would need to identify those factors that determine severity of disease and then find a method to quantify those factors (based on existing literature or new research) to come up with different levels of severity, formulating a scoring system which should be independent of local health systems. Until our meeting, you can think of those pathophysiologic and clinical indicators that you would recommend to define severity of thalassemia syndromes. It should be noted that a similar exercise has been recently conducted by Cappellini and colleagues (EJIM 2016) who developed a scoring system for non-transfusion-dependent thalassemia. We can use this as a starting model to go through the same exercise for all thalassemia phenotypes. Furthermore, we will discuss how to validate this scoring system. To do that we can either get a large data set and look at the association between the newly developed scoring/classification system against outcomes.

Finally, if consensus is reached we will aim to submit our results to a leading international journal.

Best regards

Antonis Kattamis, Khaled Musallam, Ali Taher, & Aurelio Maggio

​Faculty – IWG Meeting

IWG MEETING PROGRAM (Module 1)

Aula Magna “M.Vignola”, Aula di Medicina, Biblioteca – Ospedale “V.Cervello”

  08.00 | 08.30 – Registrations

   PLENARY ROOM (AULA MAGNA “M. VIGNOLA”)

  
  08.30 | 08.45 – Welcome address

    Antonis Kattamis (Greece), Aurelio Maggio (Italy), Maria Domenica Cappellini (Italy)

 

  08.45 | 09.00 – Greetings from local Authorities

 

  09.00 | 09.15 – Introduction: Is it time to revisit classification of Thalassemia Syndromes ?

    Aurelio Maggio (Italy)

 

  SESSION I – THALASSEMIA MAJOR AND ANTIVIRAL TREATMENT 

   CHAIRPERSONS: Antonis Kattamis (Greece), Antonio Piga (Italy)

  
  09.15 | 09.30 – Transfusion therapy: what is new with respect to safety and control of iron loading?

    Yesim Aydinok (Turkey)

 

  09.30 | 09.45 – The future of thalassemia patients without HCV infection: a new history

   Vito Di Marco (Italy)

 

  09.45 | 10.30 – Interactive Discussion: what is the state of art in transfusion safety and anti-viral treatment of Thalassemia Syndromes worldwide ? Comparing experiences from France, India, Iran, Italy, Saudi Arabia:

   Caterina Borgna Pignatti (Italy), Olivier Hermine (France), Farrukh Shah (KSA), Alok Srivastava (India)

 

  10.30 | 10.45 – Discussion

 

  10.45 | 11.00  – Coffee Break

 

  SESSION II – THALASSEMIA INTERMEDIA:

   CHAIRPERSONS: Caterina Borgna Pignatti (Italy), Vip Viprakasit (Thailand)

 

  11.00 | 11.20 – Thalassemia Intermedia: is disease morbidity as we know it today less severe than Thalassemia Major ?

    Maria Domenica Cappellini (Italy)

 

  11.20 | 11.40 – Hypercoagulable state in thalassemia

   Eliezer Rachmilewitz (Israel)

 

  11.40 |12:00 – General insights and current management of Thalassemia Intermedia

   Maria Domenica Cappellini (Italy)

 

  12.00 | 12.40 – Interactive Discussion: what is the state of art in Thalassemia Intermedia management worldwide? Comparing experiences from Iran, Italy, Malaysia, Qatar:

    Ibrahim Hishamshah (Malaysia), Paolo Ricchi (Italy), Mahamoud Yassin (Qatar)

 

  12.40 | 13.00 – Discussion

 

  
  13.00 | 14.00 – Light Lunch
   
   SESSION III – THE NEW ERA OF CHELATION TREATMENT:

    CHAIRPERSONS: Adriana Ceci (Italy), John Porter (UK)

 

   14.00 | 14.15 – How the era of the new chelators is changing prognosis of Thalassemia Syndromes

    John Porter (UK)

 

  14.15 | 14.30 – Effectiveness and safety of 10 different regimens for controlling iron overloading in Thalassemia Major

   Aurelio Maggio (Italy)

 

  14.30 | 14.45 – Iron overload and Chelation Therapy in Thalassemia Intermedia

   Maria Domenica Cappellini (Italy)

 

  14.45 | 15.30 – Interactive Discussion: what is the state of art in chelation management of Thalassemia Syndromes worldwide ? Comparing experiences from Italy, Kuwait, Oman, Pakistan, Cipro:

   Kunle Adekile (Kuwait), Shahina Daar (Oman), Aldo Filosa (Italy), Saqib Hussein Ansari (Pakistan), Soteroula Christou (Cipro)

 

  15.30 | 15.45 – Discussion
   
  SESSION IV – HIGHLIGHTS IN MANAGEMENT OF THALASSEMIA SYNDROMES IN EASTERN COUNTRIES:

   CHAIRPERSONS: Marie-Charlotte Bouesseau (Switzerland), Suthat Fucharoen (Thailand)

 

  15.45 | 16.05 – Management of Thalassemia Syndromes in Egypt: what has been changing during the last 10 years?

   Amal El-Beshlawy (Egypt)

 

  16.05 | 16.25 Current management of Thalassemia Syndromes in Thailand: past, present and future

   Vip Viprakasit (Thailand)

 

  16.25 | 16.45 – Discussion

 

  SESSION V – MRI AND CURRENT MANAGEMENT OF THALASSEMIA SYNDROMES:

   CHAIRPERSONS: Gian Luca Forni (Italy), Paul Telfer (UK)

 

  16.45 | 17.05 – The impact of MRI in changing prognosis of Thalassemia Major

   Tim St Pierre (Australia)

 

  17.05 | 17.25 – The MIOT network: an Italian model for management of Thalassemia Syndromes

   Alessia Pepe (Italy)

 

  17.25 | 18.15 – Interactive Discussion: what is the state of art in MRI facilities worldwide? Comparing experiences from Egypt, France, India, Saudi Arabia and Thailand:

   Amal El-Beshlawy (Egypt), Olivier Hermine (France), Alok Srivastava (India), Farrukh Shah (KSA), Vip Viprakasit (Thailand)

 

  18:15 | 18.30 –  Discussion

 

  SESSION VI – NOVEL STRATEGIES FOR THE TREATMENT OF THALASSEMIA SYNDROMES:

   CHAIRPERSONS: Paolo Moi (Italy), Maria Domenica Cappellini (Italy)

 

  18.30 | 18.50 – Highlights on gene therapy in haemoglobinopathies

   Marina Cavazzana (France)

 

  18:50 | 19.10 – New pharmacological approches for increasing hemoglobin levels in Thalassemia Syndromes

   Antonio Piga (Italy)

 

  19.10 | 19.30 – Conclusions

   Aurelio Maggio (Italy)

 

  19.30 | 19.45 – Hepcidin and iron overload (NO CME)

Sponsored talk by La Jolla Pharmaceutical Lakhmir S. Chawla (US)

   SESSION VII (Simultaneous sessions)
       Panel discussion on RECOMMENDATIONS FOR INITIAL EVALUATION AND STAGING ASSESSMENT OF THALASSEMIA SYNDROMES

 

   08.30 | 10.30 –  PANEL I (PLENARY ROOM: AULA MAGNA “M.VIGNOLA”

    CHAIRPERSONS: John Porter (UK)

    Antonis Kattamis (Greece)

    DISCUSSANTS: Marie-Charlotte Bouesseau; Marina Cavazzana, Gianluca Forni, Suthat Fucharoen, Olivier Hermine, Ansari Saqib Hussain, Antonio Piga, Paolo Ricchi, Farrukh Shah, Alok       Srivatsava, Paul Telfer, Vip Viprakasit

 

   08.30 | 10.30 – PANEL II (MEETING ROOM: BIBLIOTECA – OSPEDALE “V. CERVELLO”)

    CHAIRPERSONS: Amal El-Beshlawy (Egypt), Maria Domenica Cappellini (Italy)

    DISCUSSANTS: Kunle Adekile, Yesim Aydinok, Caterina Borgna Pignatti, Maria Domenica Cappellini, Adriana Ceci, Shahina Daar, Vito Di Marco, Aldo Filosa, Ibrahim Hishamshah, Aurelio Maggio, Alessia Pepe, Eliezer Rachmilewitz, Mahmoud Yassin

 

   10.30 | 10.45 –  Coffee Break
      PLENARY ROOM (AULA MAGNA “M. VIGNOLA”)

    CHAIRPERSONS: Aurelio Maggio (Italy), Maria Domenica Cappellini (Italy), Paul Telfer (UK), Antonio Piga (Italy)

 

   10.45 | 11.15 – Presentation of Panel I – Recommendations for initial evaluation and staging assessment of Thalassemia Syndromes

    Antonio Piga (Italy), Antonis Kattamis (Greece)

 

   11.15 | 11.45 – Presentation of Panel II – Recommendations for initial evaluation and staging assessment of Thalassemia Syndromes

    Amal El-Beshlawy (Egypt), Maria Domenica Cappellini (Italy)

 

   11.45 | 12.30 – Discussion for general consensus on Presentations of Panel I and II

 

   12.30 | 13.00 – Final proposal and future strategy

    Aurelio Maggio (Italy)

 

   13.00 | 13.15 – CME questionnaire

 

 

   13.15 | 13.30 – Closing remarks

    Aurelio Maggio (Italy)

 

   13.30 | 14.30 – Light Lunch

 

 

   SESSION VII (Simultaneous sessions)
   14.30 | 17.30 ORAL COMMUNICATIONS (NO CME)

CHAIRPERSON: Saqib Hussain Ansari (Pakistan)

– Molecular Analysis and Identification of Rare HbE/Beta Thalassemia Mutations in Peninsular Malaysia

Aziz Nur-Aisyah (Malaysia)

– CRISPR-mediated Gene Modification of Hemopoeitic Stem Cells in Beta Thalassemia IVS1-110 Mutation

Hala Gabr (Egypt)

– Prenatal Diagnosis and Management of Alpha-Thalassemia in DCDA Twins

Tachjaree Panchalee (Thailand) 

– Premarital testing in Kuwait

Najat Roohaldeen (Kuwait)

   16.00 | 17.30 – Poster Session II on HIGHLIGHTS IN MANAGEMENT OF THALASSEMIA SYNDROMES IN EASTERN COUNTRIES, MRI AND CURRENT MANAGEMENT OF THALASSEMIA SYNDROMES AND NOVEL STRATEGIES FOR THE TREATMENT OF THALASSEMIA SYNDROMES (NO CME)
   17.30 | 17.45 – Conclusions

    Aurelio Maggio (Italy) 

TRAINING COURSE

15 – 23 Sept

International Meeting
1st International Working Group on Thalassemia: is it time to revisit classification of Thalassemia Syndromes?

Main Topics

  • Thalassemia Major: how had conventional treatment been changing survival?
  • Current survival of Thalassemia in eastern countries: the Iranian experience
  • Thalassemia Intermedia: is disease morbidity observed today less severe compared with Thalassemia Major?
  • The role of current chelation treatment in improving prognosis of Thalassemia Major and Intermedia
  • The impact of new direct anti-viral treatment in improving prognosis of Thalassemia Syndromes
  • What is the impact of novel chelators or new formulations of available chelators treatments on outcomes in Thalassemia Syndromes?
  • Current state of total body iron burden in Thalassemia Major and Thalassemia Intermedia determined by MRI: which is the difference in terms of Liver Iron Concentration?
  • Practical training for the use of C-licnet as tool for the management of thalassemia syndromes
  • Transfusion therapy: what it has been changing with respect to satefy and control of body iron loading?
  • How much are novel innovative therapies expected to influence the prognosis of Thalassemia Syndromes?
  • Gene therapy for Thalassemia and Sickle-Cell-Disease: what it will be the future impact of procedure on this disease?

GO TO IWG MEETING PROGRAM

Introduction to the course: Santina Acuto

Prenatal Diagnosis and Genotype – Phenotype Correlation

Chairperson: Paolo Moi (Italy)

8:30 – 8:50 – Counselling and prenatal diagnosis Antonis Kattamis (Greece)

8:50 – 9:10 – Genotype-phenotype correlations Antonio Piga, (Italy)

9:10 – 9:30

                   QNajat Roohaldeen, Tachjaree Panchalee, Mara Memoli, Hala Gabr, Valeria Cento, Wael Aboulkheir, Nur Aisyah Aziz

                   A: Antonis Kattamis and Antonio Piga

Proposed Questions to be addressed:

  • How to counsel the couple for beta thal/HbE disease with low severity or predictive factors to decrease the severity of disease?
  • How different factors in severity of HbH disease (non-depedent vs depedent blood transfusion)?
  • What is the “flowchart” for prenatal diagnosis of thalassemia?
  • Which mistakes may I make in taking clinical decision on the basis of genotype?
  • Which is the target population?
  • Which are the main reasons for failure on the thalassemia prevention programs?
  • How to do best for the counselling?
  • According to the high complication of PND test for pregnant mothers and false negative results, development of another test such as Pre Implantation Genetic Diagnosis (PGD) is necessary, so what are the methods for simplifying the performance of these?
  • According of Iran Health Ministry data, the new case of B-thalassemia are 250 newborn patients per year. This happens performing two screening tests in the last years. Therefore, which are the useful methods in order to decrease the birth-rate newborn with B-thalassemia?
  • Which is the cut off value of HB A2 to screen for silent beta thalassemia trait?
  • Which is the different clinical phenotype of silent beta thalassemia?
  • Which is the significance of coinheretence rare hemoglobin band e.g HB Hope
  • Which is the most recent and easy molecular methods for detection of thalassemia mutation  to be used in  hematology Lab?

 

 

Current management of ß-thalassemias and hypercoagulable state 

Chairperson: Antonio Piga, Italy

 

9:30 – 9:50 – Current management of ß-thalassemias Alan Cohen (USA)

9:50 – 10:10 – Hypercoagulable State on Thalassemia Eliezer Rachmilewitz, (Israel)

10:10 – 10:30 Q : Q. Najat Roohaldeen, Tachjaree Panchalee, Mara Memoli, Hala Gabr, Valeria Cento, Wael Aboulkheir, Nur Aisyah Aziz A: Antonis Kattamis and Elezier Rachmilewitz

                                 A: Alan Cohen and Elezier Rachmilewitz 

10:30 – 10:45   Coffee Break

 

Proposed Questions to be addressed:

What is the pathophysiology of the multiple silent cerebral lesions in patients with Thal major and intermedia?

Identify the characteristics of an optimal unit of donor red cells for transfusion in thalasse- mia major.

What are the most important indications for splenectomy in thalassemia major.

Identify at least one appropriate use of each of the three available iron chelators.

What are the therapeutic options for Hypercoagolable state in Thalassemia?

Which are the main indicators to change chelation treatment?

Which are the main predictors of diease prognosis?

Which is the limit of serum ferritin levels in the management of thalassemia iron overloading ?

Which are the main parameters for deciding to start chelation treatment?

How to manage iron overloading in anemic women during pregnancy ?

 

 

Sickle-Cell Disease and Gene Therapy

Chairperson:  Elezier Rachmilewitz  (Israel)

 

10:45 – 11:05 – Sickle Cell Disease: past, present and future Paul Telfer (UK)

11:05 – 11:25 – Gene Therapy for Hemoglobinopathies Paolo Moi (Italy) 

11:25 – 11:45 Q:  Najat Roohaldeen, Tachjaree Panchalee, Mara Memoli, Hala Gabr, Valeria Cento, Wael Aboulkheir, Nur Aisyah Aziz A: Paul Telfer and Paolo Moi

                              A: Paul Telfer and Paolo Moi

 

Proposed Questions to be addressed :

  • Please describe the background for design of CRISPR for gene correction of thalassemia and sickle cell disease
  • May you give me an overview of genome editing approaches for gamma-globin gene reactivation?
  • Which is the role of bone marrow transplantation in the care of people with SCD?
  • Which are the prevalent phenotype of Sickle Cell carriers ?
  • Which are the main prognostic factors of SCD?
  • Intrauterine gene therapy for hematological diseases, can it be possible?
  • What are the current indications for treatment of sickle cell disease with (1) hydroxyurea and (2) regular blood transfusion?

 

 

Tissue Iron Measurement by MRI

Chairperson: Paul Telfer (UK)

 

11:45 – 12:05 – Tissue Iron Measurement by MRI: Advances, Challenges, and Pitfalls Tim St Pierre (Australia)

12:05 – 12:25 – C-licnet Network: potential worldwide MRI network for the management of thalassemia syndromes Aurelio Maggio (Italy)

12:25 – 12:45 Q: Q:Najat Roohaldeen, Tachjaree Panchalee, Mara Memoli, Hala Gabr, Valeria Cento, Wael Aboulkheir, Nur Aisyah Aziz                           

                          A: Tim St. Pierre and Aurelio Maggio

Sponsored by Agilent:

Chairperson: Santina Acuto

12:45 – 13:10 – Measuring Mitochondrial function and Glycolysis for the Metabolic Phenotype detection in Hematological Disease E. Di Capua (Italy)

13:10 – 13:30 – Genomic strategies for target capture in onco-hematology A. Agostino (Italy)

Closing remarks: Aurelio Maggio (Italy)

 13.30 – 14.30 Light Lunch

 

Proposed Questions to be addressed :

  • Which are the organs where the determination of iron by MRI is crucial?
  • Which are the limits of MRI measurements?
  • Which are the cut-off of heart and liver iron overloading that I have to monitor for changing chelation treatment?
  • Which are the options for managing iron overloading if I do not have access to MRI or this access is limited?
  • Which is the timing to repeat LIC and Heart MRI determinations in the patients?

 

 

 

TRAINING COURSE

CLINIC TRAINING in cooperation with the Clinical Nursing Coordinator G. Di Liberto and the Vice Clinical Nursing Coordinator A. Travia

  • How and when to change chelation in TM and TI L. Pitrolo, A. Giangreco
  • C-licnet training G. Padovano, L. Tesè
  • Heart Functional Studies L. Mancuso, G. Carmina
  • Approach to the patient with SCD: what is changing? R. Di Maggio, D. Renda
  • Management of direct anti-HCV drugs in Hemoglobinopathies S. Madonia, R. Barone
  • Management of HCC in Thalassemia Syndromes R. Virdone, R. Volpes (ISMETT)

HPLC TECHNOLOGY AND DATA INTERPRETATION S. Marivoet (sponsored by Tosoh)

  • Training(20′)
  • Q&A(10′)

PRENATAL SAMPLING

  • Practical training on celocentesis, villocentesis and amniocentesis F. Damiani, V. Cigna, G. Schillaci, E. Orlandi

MOLECULAR DIAGNOSIS (route laboratory from the identification of carrier to prenatal diagnosis of thalassemia and other rare Haematological disorders)

  • First-level diagnosis of ß-thalassemia carrier A. Giambona, M. Cannata
  • Interpretation of phenotype and correlation with genotype A. Giambona, M. Vinciguerra
  • Second-level diagnosis for genetic disorders: sequencing, array-CGH and Next-Generation F. Leto, C. Passarello, M. Crivello
  • Diagnostic and Molecular approach of Congenital dyserythropoietic anemias F. Listì, V. Agrigento, S. Sclafani
  • Prenatal genetic counselling A. Giambona, A. Maggio
  • Prenatal diagnosis, molecular analysis F. Cassarà, M. Vinciguerra

RESEARCH

  • Fertility: gametes cryopreservation M. C. Renda, R. Schillaci, N. Minniti, M. Fecarotta
  • Erythroid Cell Culture as model for induction of Fetal Hemoglobin A. Pecoraro, A. Troia
  • Citofluorimetry as tool in Haematological rare diseases studies A. Pecoraro, A. Troia
  • Cell Sorting for isolation of single cell J. A. Formaro (sponsored by Beckman Coulter)
  • Hematopoietic Stem Cell transduction by Recombinant – Lentiviral Vectors S. Acuto, E. Baiamonte, M. Lo Iacono, R. Di Stefano

GO TO APPLICATION FORM

Dates:

  • Module 1 • September 15-16, 2017
  • Module 2 • September 17, 2017
  • Module 3 • September 18-23, 2017

Course Objective:

The main aim of the course is to bring together experts and young researchers, clinicians and biologists, in order to address key issues in the field of Rare Haematological Diseases. The course is organized into individual sessions to provide a versatile and unique opportunity to get an overview of Rare Haematological Diseases, with particular reference to haemoglobinopathies. For the theoretical part, participants may attend the international meeting and the keynote lectures given by world leaders in the field. For the practical part, attendees will be trained through specific routes ranging from prenatal sampling techniques to laboratory and clinical paths, and to innovative research.

Audience:

  • Haematologists, Gynecologists (with particular regards to Prenatal Diagnosis Specialists)
  • Biologists, Biotecnologists
  • Radiologists
  • Medical Technicians

Course Directors:

  • Aurelio Maggio – Italy
  • Santina Acuto – Italy

International Scientific Board:

  • Alan Cohen – USA
  • Ali Taher – Lebanon
  • Suthat Fucharoen – Thailand
  • John Porter – UK

Application Deadlines:

  • Module 2 & 3: July 20, 2017
  • Module 1 only: July 20, 2017

All applications will be submitted to our International Scientific Board. We anticipate being able to notify applicants regarding their applications during the second half of July 2017.

Required Documents for participation:

The following supporting documents should be submitted:

  • Curriculum Vitae (CV) – short version
  • Official Medical School Transcript
  • Personal Statement
  • Two (2) letters of reference, including one from your program director.

For further information, please contact the organizing secretariat

Giusy Ventura | Congress Specialist

Collage S.p.A.
  • e-mail: giusy.ventura@collage-spa.it
  • Office: +39 091 6867 413 direct
  • Mobile: +39 335 1276715

PRESENTATIONS

CAMPUS OF HAEMATOLOGY “FRANCO E PIERA CUTINO”

The Campus of Haematology “Franco e Piera Cutino” is a pioneering center for prevention, care and research on thalassemia and haemoglobinopathies, and for the reception of patients’ families and their guests.

The structure was inaugurated on May 8 2013 at the Hospital “V.Cervello”, A.O.O.R. “Villa Sofia – V.Cervello” of Palermo, under the agreement between the Foundation “Franco e Piera Cutino”, the Association for Research “Piera Cutino” Onlus, the U.O.C. Haematology for Rare Diseases of Blood and Haematopoietic Organs and the Health Department of the Regione Sicilia.

The Campus was made entirely through private fundraising organized during the years by the Association for Research “Piera Cutino”, non-profit organization established in 1998 by the Cutino family.
A dream has become a real fact. The Campus was born from the spirit of solidarity and openness to life that has inspired the work and the activities of the Cutino family and especially of Franco, who suffered from the loss of her daughter Piera, a 23 year old girl ill with Thalassemia in 1982. Since that sad event, Franco Cutino has dedicated his life to the commitment and fundraising for the improvement of the thalassemia patients and their families condition of assistance, and for funding research aimed at the discovery of a possible therapy.

In 2003, shortly before his death, Franco Cutino dreamed of a large building, white and blue, the colors of the sky and sea: a place entirely dedicated to the care of thalassemia and other rare blood diseases. Today the Campus reproduces, also in the architecture and colors, the image Franco dreamed.

The dream became a concrete reality thanks to the synergy and close collaboration over the years between the Association “Piera Cutino,” the Foundation “Franco e Piera Cutino”, set up in 2005, and the U.O.C. Haematology for Rare Diseases of Blood and Haematopoietic Organs, directed by the Professor Aurelio Maggio.

PURPOSES

The Campus of Haematology “Franco e Piera Cutino” stands as center of excellence for the whole country.
Its purposes are:

  • prevention, care, basic and applied research in the field of thalassemia and rare hematological diseases;
  • patient care (with Day Hospital Area, Hospitalization Area, Sterile Unit for transplant patients, Transfusion Rooms, Toy Library, Home Therapy Service);
  • training of doctors, biologists, engineers and highly qualified team coming from the Mediterranean area;
  • the reception by the accommodation “CasAmica”, designed to host the families of all hospital patients and other guests of the Campus.

PRESS REVIEW

Where to stay

Finding a good hotel can be tricky. So here are some of our favorite hotels nearby event location

NH Palermo

Visit Website

Casa Amica

Visit Website

Comune di Palermo

Visit Website

Terms and conditions
Booking and Payment

All prices are quoted in Euros and do not include 22% VAT. Rooms will be confirmed only on receipt of a signed Booking Form. Confirmation will be sent together with a tax invoice for the required 50% deposit. The deposit is payable by 15 days from the date of the tax invoice. The balance will be invoiced on 20 June 2017, to be paid by 20 July 2017. Applications after this date must include full payment. All payments should be made in Euros to the following bank account:

COMITATO INTERNATIONAL GROUP FOR THALASSEMIA

IBAN: IT37 E033 5901 6001 0000 0151 884

BIC: BCITITMX

Please note that your registration will only be valid when full payment is received by the administrative office. Payment done by bank transfer must be certified with the copy of the receipt of the bank to be uploaded in the registration form or sent to e-mail to giusy.ventura@collage-spa.it

Cancellation Policy

If notification of cancellation is received in writing:

  • between 1 May 2017 and 20 June 2017, you are liable for 50% of the package selected
  • from 20 June you are liable for 100% of the package selected.

The Organizing Committee reserves the right to cancel the Congress not later than 15 August 2017 in case of circumstances beyond its control. In such a case all monies paid to date will be refunded in full less any expenses incurred. The liability of the organisers will be limited to that amount.

Our Faculty members possess a strong academic and professional background and years of relevant work experience.

Thank you for taking the time to consider the possibilities this International Meeting has to offer. If you have made your choices, please complete and return to us the application form. If we can assist with further information, please contact the Organizing Secretariat. We hope that you are as enthusiastic about the opportunities that are available as we are and look forward to welcoming you to Palermo in September 2017.

ACKNOWLEDGMENTS

We thank Foundation Franco and Piera Cutino for the support to the organization of the course. Moreover, we thank Dr. Paolo Chiesi for his personal kind support aimed at theorganization of this event.

OUR SPONSORS

Event is supported by easily recognisable companies and products which we use everyday.

GET DIRECTIONS

Fill the form below to get directions to our event location

Enter Direction from and Travel Mode from the left form to see directions.

ADDRESS

Campus of Haematology ” Franco e Piera Cutino”

Via Trabucco, 180

90146 Palermo

Italy

 

CONTACT

Collage S.p.A. CME Provider and Organizing Secretariat

giusy.ventura@collage-spa.it

www.collage-spa.it

tel. +39 091 688 5506

 

SEND US A MESSAGE

If you have any questions about the event, please contact us directly. We will respond for sure.






IWG ON THALASSEMIA

JOIN THE EVENT

back to top